MedTrace Logo

Botulium Toxin Type A In Non Infectious Chronic Rhinosinusitis

NCT04572516 · Status: COMPLETED · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 30

Last updated 2021-07-23

No results posted yet for this study

Summary

The present work aims to assess the effectiveness and safety of topical application of BTX - A compared with its intra turbinate injection in controlling the symptoms in non infectious chronic rhinosinusitis patients

Conditions

  • Chronic Rhinosinusitis (Diagnosis)

Interventions

DRUG

BTX A Topical

In group A (topical group) ,topical application in the form of merocel soaked with 20 units of BTX\_A (2ml) will be placed at each side of the nasal cavity for 30 minutes.

DRUG

BTX A Injection

In group B (injected group), 20 units of BTX\_A(2ml) will be injected submucosally in each inferior turbinate using insulin syringe needle after local anesthesia using 10% xylocaine spray .

Sponsors & Collaborators

  • Benha University

    lead OTHER

Principal Investigators

  • Abdelrahman A Abdelalim, MD · Benha University

  • Mohamed A Elsayed, MD · Benha University

  • Naslshah G Kazeem, MD · Benha University

  • Aya L Hassan, Resident · Benha University

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2020-05-01
Primary Completion
2021-06-15
Completion
2021-07-15

Countries

  • Egypt

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04572516 on ClinicalTrials.gov